Determination of tissue plasminogen activator and its "fast" inhibitor in plasma.

Chmielewska, Joanna; Wiman, Björn

doi:10.1093/clinchem/32.3.482

Cited by 189 publications

(50 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fibrinogen was measured according to the Clauss (1957) method (Fibri-Prest Aut from STAGO, Asnieres-sur-Seine, France) with a total coefficient of variation (CV) of 4% at 1·7 g / l and 5% at 2·6 g / l. An enzyme-linked immunosorbent assay (ELISA; Coalisa-tPA, Haemochrom Diagnostica, Mölndal, Sweden; Holvoet et al, 1985) with a total CV of 14% was used to measure t-PA antigen. PAI-1 activity was determined using Spectrolyse (Biopool, Umeå, Sweden; Chmielewska & Wiman, 1986) with a total CV of 13%. IGF-I was determined by a radioimmunoassay as described previously (Leonsson et al, 2002).…”

Section: Methodsmentioning

confidence: 99%

Increased Interleukin‐6 levels in pituitary‐deficient patients are independently related to their carotid intima‐media thickness

Leonsson¹,

Hulthe

Johannsson³

et al. 2003

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Increased Interleukin‐6 levels in pituitary‐deficient patients are independently related to their carotid intima‐media thickness

Leonsson¹,

Hulthe

Johannsson³

et al. 2003

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…The ELISA (MacGregor & Booth, 1988) was modified as described previously . PAI activity assay was based upon neutralization of t-PA (Chmielewska & Wiman, 1986). T-PA antigen was assayed by ELISA (MacGregor et al, 1987).…”

Section: Subjects Healthy Volunteers Aged Between 25 and 40 Werementioning

confidence: 99%

The Effects of Chronic Smoking on the Fibrinolytic Potential of Plasma and Platelets

et al. 1997

View full text Add to dashboard Cite

Summary.We studied tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in healthy individuals divided by smoking habit into current smokers, former smokers and non-smokers (who had never smoked). Plasma PAI-1 antigen was significantly higher in smokers than in non-smokers with intermediate levels in former smokers. A similar trend was observed for plasma PAI activity but this did not reach statistical significance. Platelet PAI-1 and plasma t-PA were not significantly different when comparing the three groups. After venous occlusion t-PA rose significantly in all groups; no significant change in plasma PAI-1 was observed. The ratio of t-PA to PAI-1 in plasma was similar in non-smokers and former smokers but lower in smokers, suggesting that there is at least partial restoration of plasma fibrinolytic potential after smoking cessation. Plasma PAI-1 antigen and PAI activity correlated with estimated pack-years of cigarettes smoked among smokers and former smokers. When all subjects were studied collectively, plasma PAI-1 correlated strongly with plasma t-PA and triglycerides; plasma t-PA also correlated strongly with triglycerdes.We conclude that chronic smoking is associated with impaired fibrinolysis in plasma and that this largely reflects elevated plasma PAI-1 in smokers. Smoking does not appear to affect the response to venous occlusion. The postulated effect of chronic smoking on plasma PAI-1 may be mediated by the influence of smoking on triglycerides and insulin resistance. Stopping smoking appears to return impaired fibrinolysis towards normal. Smoking does not quantitatively affect the platelet pool of PAI-1. Smoking habit should be controlled for in clinical analyses of PAI-1 and t-PA.

show abstract

“…PAI-1 antigen and activity and t-PA antigen were determined on citrated plasma samples (Chmielewska & Wiman, 1986). For determinations of t-PA activity plasma from blood sampled in commercially available tubes containing acidified citrate (Biopool AB, Umeta, Sweden) was used (Chmielewska & Wiman, 1986). For…”

Section: Fibrinolysismentioning

confidence: 99%

Effects of an oral dose of isosorbide dinitrate on platelet function and fibrinolysis in healthy volunteers.

Wallén

Larsson

Bröijersén

et al. 1993

Brit J Clinical Pharma

View full text Add to dashboard Cite

1. A randomised double‐blind placebo‐controlled study was performed to investigate the effects of isosorbide dinitrate (ISDN; 20 mg orally) on various aspects of platelet function and fibrinolysis in vivo in 12 healthy volunteers. 2. Measurements were performed at rest (before and after tablet ingestion) and during platelet activation by adrenaline (0.4 nmol kg‐1 min‐1; 30 min infusion). 3. At rest, ISDN did not alter plasma concentrations of beta‐thromboglobulin (beta TG). EC50 values for ADP induced aggregation in vitro (Born aggregometry) or ex vivo filtragometry readings. Adrenaline markedly increased platelet aggregability in vivo as measured by filtragometry and elevated levels of beta TG in plasma. ISDN treatment did not affect these responses in the group as a whole. 4. Individuals responding to ISDN with more pronounced vasodilatation at rest showed a lesser increase in aggregability during the ensuing adrenaline infusion (r = ‐0.66, P = 0.02) despite higher adrenaline levels during ISDN. In individuals showing a significant decrease in systolic blood pressure (n = 8) ISDN tended to attenuate the adrenaline induced increase in platelet aggregability (filtragometry; P = 0.08), despite higher plasma adrenaline and noradrenaline levels after ISDN ingestion. 5. Plasma concentrations of ISDN and its active metabolites isosorbide‐5‐ mononitrate and isosorbide‐2‐mononitrate were not correlated to haemodynamic or platelet variables. 6. Fibrinolytic activity (t‐PA antigen and activity, PAI‐1 antigen and activity) increased similarly during the adrenaline infusion following ISDN and placebo. 7. It is concluded that ISDN may affect platelet aggregation responses to adrenaline in vivo, but only in individuals showing significant haemodynamic responses to ISDN.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Determination of tissue plasminogen activator and its "fast" inhibitor in plasma.

Cited by 189 publications

References 0 publications

Increased Interleukin‐6 levels in pituitary‐deficient patients are independently related to their carotid intima‐media thickness

Increased Interleukin‐6 levels in pituitary‐deficient patients are independently related to their carotid intima‐media thickness

The Effects of Chronic Smoking on the Fibrinolytic Potential of Plasma and Platelets

Effects of an oral dose of isosorbide dinitrate on platelet function and fibrinolysis in healthy volunteers.

Contact Info

Product

Resources

About